Video

Dr. Abou-Alfa on Ramucirumab as Second-Line Therapy for Hepatocellular Carcinoma

Ghassan K. Abou-Alfa, MD, discusses the role of ramucirumab in the treatment of patients with hepatocellular carcinoma in the second-line setting.

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of ramucirumab (Cyramza) in the treatment of patients with hepatocellular carcinoma (HCC) in the second-line setting.

Based on data from the phase III REACH-2 trial, the FDA granted approval to ramucirumab monotherapy in May 2019 for the treatment of patients with HCC who have an alpha-fetoprotein (AFP) level of ≥400 ng/mL and have been previously treated with sorafenib (Nexavar), explains Abou-Alfa. While ramucirumab is only applicable to patients with this elevated level of AFP, elevated AFP levels are still complex to understand, according to Abou-Alfa.

Elevated AFP can occur due to a number of causes, including worsening disease, liver functionality, or the etiology of the disease, says Abou-Alfa. Elevated AFP and its causes require further investigation, he concludes.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Andrew Ip, MD
Mansi R. Shah, MD
Elizabeth Buchbinder, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Alec Watson, MD
Sagar D. Sardesai, MBBS
Ashkan Emadi, MD, PhD
Matthew J. Baker, PhD
Manmeet Ahluwalia, MD, MBA, FASCO
John Mascarenhas, MD